doi: 10.1111/joim.12629

Hydrochlorothiazide use is strongly associated with risk of lip cancer

A. Pottegård1, J. Hallas1, M. Olesen1, M. T. Svendsen2, L. A. Habel3, G. D. Friedman3 & S. Friis4

From the 1Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark; 2Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark; 3Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA; and 4Danish Cancer Society, Danish Cancer Society Research Center, Copenhagen, Denmark

Abstract. Pottegård A, Hallas J, Olesen M, Svendsen MT, Habel LA, Friedman GD, Friis S (University of Southern Denmark; Odense University Hospital, Odense, Denmark; Kaiser Permanente Northern California, Oakland, CA, USA; Danish Cancer Society, Copenhagen, Denmark). Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282: 322–331.

Background. The diuretic hydrochlorothiazide is amongst the most frequently prescribed drugs in the United States and Western Europe, but there is suggestive evidence that hydrochlorothiazide use increases the risk of lip cancer.

Objectives. To study the association between use of hydrochlorothiazide and squamous cell carcinoma of the lip.

Methods. We conducted a case–control study using Danish nationwide registry data. From the Cancer Registry (2004–2012), we identified 633 case patients with squamous cell carcinoma (SCC) of the lip and matched them to 63,067 population controls using a risk-set sampling strategy. Hydrochlorothiazide use (1995–2012) was obtained from the Prescription Registry and defined according to cumulative use. Applying conditional logistic regression, we calculated odds ratios (ORs) for SCC lip cancer associated with hydrochlorothiazide use, adjusting for predefined potential confounders obtained from demographic, prescription and patient registries.

Results. Ever-use of hydrochlorothiazide was associated with an adjusted OR for SCC lip cancer of 2.1 (95% confidence interval (CI): 1.7–2.6), increasing to 3.9 (95%CI: 3.0–4.9) for high use (≥25,000 mg). There was a clear dose–response effect (P < 0.001), with the highest cumulative dose category of hydrochlorothiazide (≥100,000 mg) presenting an OR of 7.7 (95%CI: 5.7–10.5). No association with lip cancer was seen with use of other diuretics or nondiuretic antihypertensives. Assuming causality, we estimated that 11% of the SCC lip cancer cases could be attributed to hydrochlorothiazide use.

Conclusions. Hydrochlorothiazide use is strongly associated with an increased risk of lip cancer.

Keywords: cancer, epidemiology, hydrochlorothiazide, pharmacology.
We recently reported the results of a screening study of drug-cancer associations [10]. Herein, we observed an association between use of a combined preparation of HCTZ and amiloride and increased risk of squamous cell carcinoma (SCC) of the lip. This finding, together with the sparse epidemiologic evidence of an association between HCTZ use and lip cancer [4] and the request for further studies of drugs classified as potentially carcinogenic by the IARC [11], prompted us to conduct more extensive analyses of the association between HCTZ use and risk of SCC lip cancer using detailed data from the Danish nationwide registries.

Materials and methods

We conducted a nested case-control analysis of nationwide registry data comparing HCTZ use amongst patients diagnosed with SCC of the lip (cases) with use amongst cancer-free persons (controls) to estimate odds ratios (ORs) for SCC lip cancer associated with HCTZ use. We obtained data from five nationwide registry sources: the Danish Cancer Registry [12], Danish National Prescription Registry [13], Danish National Patient Registry [14], Danish Education Registries [15] and Danish Civil Registration System [16, 17]. The Supplementary Material provides a detailed description of the registries (Appendix S1) with codes for tumour characteristics, drug exposure and covariates (Appendix S2).

Case selection

Cases were all Danish residents with a biopsy-verified first diagnosis of SCC of the lip between 1 January 2004 and 31 December 2012. Cases had no history of cancer (except nonmelanoma skin cancer) prior to the lip cancer diagnosis (index date), were continuous residents in Denmark for at least 10 years prior to the index date and had no record of organ transplantation, azathioprine use or diagnoses of HIV or AIDS (because of the association between immunosuppression and skin cancer) [18–21].

Control selection

For each case, using a risk-set sampling strategy, we selected 100 controls amongst all Danish residents matched by sex and birth year, applying the same exclusion criteria as for cases. The index dates used for controls were identical to the dates of the corresponding cases. Persons were eligible as controls before they became cases. Therefore, the calculated ORs provide unbiased estimates of the incidence rate ratios that would have emerged from a cohort study based on the source population [22].

Exposure assessment

Ever-use of HCTZ was defined as having filled at least one prescription for a HCTZ-containing drug prior to the index date; never-use was defined as no such prescriptions. In Denmark, HCTZ is prescribed almost exclusively in combination preparations with nondiuretic antihypertensives or with the potassium-sparing diuretic amiloride. We defined high use of HCTZ as filled prescriptions equivalent to ≥25 000 mg of HCTZ, corresponding to approximately 3 years of cumulative use (1000 defined daily doses [23]).

Prescriptions filled within 2 years before the index date (lag-time) were disregarded to allow a reasonable induction period for an effect on lip cancer risk and to guard against the possibility that increased medical attention before the cancer diagnosis influenced prescribing of HCTZ, introducing ‘reverse causation’ [24]. In sensitivity analyses, we varied the length of the lag-time.

Analytical variables

We based potential confounder selection on data available in nationwide prescription, patient and education registries: (i) use of selected drugs with suggested photosensitizing properties, including oral retinoids, topical retinoids, tetracycline, macrolides, aminoquinolines and amiodarone [9, 25–27]; (ii) use of drugs with suggested cancer chemopreventive effects, including aspirin, nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) and statins [11]; (iii) history of diabetes, chronic obstructive pulmonary disease (COPD) and conditions associated with heavy alcohol consumption, derived from composite measures of hospital diagnoses and prescription use of disease-specific drugs (see Appendix S2); (iv) history of nonmelanoma skin cancer; (v) average Charlson Comorbidity Index (CCI) scores [28, 29] (0 low; 1–2: medium; or ≥3: high), derived from diagnoses of 19 chronic conditions; and (vi) highest achieved education (short; medium; higher; unknown) as a measure of socio-economic status. Exposure to each potential confounder drug was defined as two or more prescriptions on separate dates, and hospital histories of each of the selected conditions...
were defined as a primary or secondary discharge or ambulatory diagnosis. As for HCTZ use, we disregarded covariate information recorded less than 2 years prior to the index date.

Main analyses

The analysis followed a conventional matched case–control approach. We computed the frequency and proportion of cases and controls within categories of the exposure and covariates. Using conditional logistic regression analysis, we computed ORs with 95% confidence intervals (CIs) for SCC lip cancer associated with HCTZ use whilst adjusting for the predefined potential confounders. The effect of age and sex was handled by the matching and conditional analysis. Additionally, to examine a potential dose–response relationship, we performed analyses stratified according to predefined categories of cumulative HCTZ use. A formal dose–response analysis was performed by restricting analyses to ever-users and estimating the incremental OR for each 25 000 mg HCTZ (capping exposure at 100 000 mg), using ordinary logistic regression whilst also adjusting for sex and age as a continuous variable. Never-use served as the reference group for all analyses unless stated otherwise.

To estimate the proportion of SCC lip cancer cases that, during our study period, could be attributed to use of HCTZ, we calculated the ‘population-level attributable proportion’ (AP pop) using the following equation: AP pop = prop cases·(OR-1)/OR. Here, prop cases denotes the proportion of all SCC lip cancer cases classified as exposed to high use of HCTZ. The applied OR was that obtained for the main analysis, that is the fully adjusted association between high use of HCTZ and SCC lip cancer.

Secondary and sensitivity analyses

We performed a number of preplanned subanalyses. First, we defined HCTZ use according to duration and intensity of use, assuming that the number of tablets represented the number of days that HCTZ was taken (whilst not allowing stockpiling). For intensity of use, we estimated the average that HCTZ was taken (whilst not allowing stockpiling) divided by the estimated cumulative duration of use. Secondly, we performed subgroup analyses according to age and sex or with restriction to specific subsets of the study population: never-user of other photosensitizing drugs (as defined above); low comorbidity (CCI score = 0); no history of diabetes; or no history of nonmelanoma skin cancer. Thirdly, we repeated the main analyses for bendroflumethiazide, besides HCTZ the most frequently prescribed thiazide in Denmark, and for the loop diuretic furosemide that has been suggested to possess photosensitizing properties [9, 25–27]. In dose–response analyses of bendroflumethiazide, we used dose categories that were 10 times lower than for HCTZ because bendroflumethiazide is considered to be about 10 times as potent [30, 31]. We also performed analyses for antihypertensives with similar indications to thiazides (that is primarily mild to moderate hypertension), including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II (ATII) antagonists and group 2 calcium-channel blockers (CCBs). Amongst CCBs, we excluded nifedipine that possesses photosensitizing properties and has been associated with an increased risk of lip cancer [4]. In Denmark, however, nifedipine prescriptions only comprise only 1.8% of the total sales of CCBs [32], precluding meaningful analyses of this drug. In analyses of other diuretics and nondiuretic antihypertensives, associations were adjusted for HCTZ use. Fourthly, we restricted HCTZ use to combination therapy with amiloride, which generated the ‘drug–cancer signal’ with lip cancer in our recent screening study [10]. Fifthly, we excluded ever-users of amiloride from the main analyses to obtain ORs for SCC lip cancer associated with HCTZ use exclusive of amiloride use. Finally, we repeated the main analyses varying the lag-time between 0 and 5 years (in steps of 6 months).

Other

All analyses were performed using STATA Release 14.1 (StataCorp, College Station, TX, USA). The Danish Data Protection Agency and Statistics Denmark’s Scientific Board approved the study. According to Danish law, ethical approval is not required for registry-based studies.

Results

Main analysis

After exclusions (n = 222), the study population comprised 633 biopsy-verified SCC cases (Fig. 1) matched to 63 067 cancer-free controls. Cases had higher comorbidity and lower educational status than controls (Table 1). The remaining characteristics were similar amongst cases and controls.
Hydrochlorothiazide was obtained mainly in combination with ATII antagonists (44% of all prescriptions filled amongst controls), amiloride (33%) and ACE inhibitors (21%). Overall, 14.8% of cases and 4.4% of controls were high-users (≥25 000 mg) of HCTZ, yielding an adjusted OR for SCC lip cancer of 3.9 (95%CI: 3.0–4.9). Analyses defining HCTZ use according to cumulative amount showed a clear dose–response pattern, with high ORs in both the predefined (≥50 000 mg: 5.5; 95%CI: 4.2–7.2) and post hoc (≥100 000 mg: 7.7; 95%CI: 5.7–10.5) upper exposure categories (Table 2). In the dose–response analysis, the incremental OR per 25 000 mg HCTZ was 1.7 (95%CI: 1.5–1.9, P < 0.001). Analyses defining HCTZ use according to duration or intensity also revealed clear trends towards higher values in the upper exposure categories (duration ≥5 years: OR, 4.5; 95%CI: 3.5–5.9; intensity ≥32.25 mg day⁻¹: OR, 4.9; 95% CI: 3.0–7.8) (Table 3). The estimation of the ‘population-level attributable proportion’ (APpop)

yielded a value of 0.11; equivalent to 11% of all SCC lip cancer cases occurring during the study period could be attributed to high use of HCTZ (assuming causality).
Secondary and sensitivity analyses

In secondary analyses of high-use HCTZ, only minor variations in ORs were seen according to age or sex or within the selected subgroups of study subjects (Table 4). In general, the adjustment for potential confounders had limited influence on the OR estimates (Table S1).

In analyses of bendroflumethiazide or CCB use, we found no apparent associations with SCC lip cancer risk, overall or according to cumulative amount, duration or intensity of use (Table 5). Similarly, we observed no associations for SCC lip cancer with use of ACE inhibitors, ATII antagonists or furosemide (Table S2).

Individual analyses of amiloride was not feasible, because almost all (>99%) amiloride was prescribed in combination with HCTZ. Excluding ever-users of amiloride, we observed a dose–response pattern for HCTZ use similar to the main analysis, that is a neutral OR for SCC lip cancer with a cumulative amount <25 000 mg (ORs 1.0–1.1), increasing to ORs of 1.7 (95%CI: 1.0–2.9) and 2.4 (95%CI: 1.0–5.8) for 25 000–49 000 mg and 50 000–74 999 mg, respectively. We could not estimate associations for a cumulative amount above 75 000 mg, as subjects with highest use of HCTZ had predominantly used the HCTZ–amiloride combination.

In analyses varying the lag-time prior to the index date, we found increasing ORs for SCC lip cancer with increasing lag-time for HCTZ exposure, from 3.1 (95%CI: 2.5–3.9) with no lag-time to 5.3 (95%CI: 4.1–6.7) with 5 years of lag-time (Table S3). The (null) association between bendroflumethiazide use and SCC lip cancer risk did not vary according to length of lag-time (data not shown).

Discussion

In this nationwide case–control study, use of the photosensitizing diuretic HCTZ was associated with a substantially increased risk of SCC of the lip. Risk increased with increasing cumulative amount, duration and intensity of HCTZ use. More than 100 000 mg of HCTZ, corresponding to more than 10 years of cumulative use, was associated with a sevenfold increased risk for SCC lip cancer. Assuming causality, an estimated 11% of all SCC lip cancer cases occurring the study period could...
be attributed to use of HCTZ. Meanwhile, use of the diuretics bendroflumethiazide or furosemide or nondiuretic antihypertensive drugs was not associated with increased lip cancer risk.

The strengths of our study are its national scale and large population, long study period and high-quality registry data with lip cancer diagnoses restricted to histologically verified SCC cases identified from the Danish Cancer Registry, which is known to have accurate and virtually complete registration of incident cancers in Denmark [12]. The use of the Danish Prescription Registry also ensured complete and high-quality assessment of drug use with up to 18 years of exposure history [13]. The main limitation was lack of information on UV exposure and tobacco smoking, the two major risk factors for lip cancer. However, we find it unlikely that HCTZ users would have markedly different sun exposure or smoking patterns than never-users. To reduce partially potential confounding by tobacco smoking, we adjusted for COPD as a crude measure of heavy smoking. We also adjusted for both individual chronic diseases and general comorbidity, estimated by average CCI scores. Differences in comorbidity might introduce bias if medical attention and thus diagnostic opportunity for lip cancer were higher amongst HCTZ users because of higher comorbidity than amongst never-users of HCTZ. However, such surveillance bias is unlikely to occur specifically amongst HCTZ users and not amongst users of other antihypertensive drugs. Notwithstanding the possibility of residual confounding by sun exposure or tobacco smoking, differences in these risk factors according to HCTZ use would need to be extremely large to account for the up to sevenfold increased ORs observed in our study.

Our findings are compatible with the results reported by Friedman et al. who found that ≥5 years of cumulative HCTZ use was associated with an OR for lip cancer of 4.22 (95%CI: 2.82–6.31) [4]. The authors observed similar results for HCTZ monotherapy. We could not evaluate association for HCTZ monotherapy, because in Denmark nearly all HCTZ was prescribed as a combination preparation with amiloride or with nondiuretic

Table 3 Association between exposure to hydrochlorothiazide and risk of squamous cell carcinoma of the lip, according to cumulative duration and intensity of hydrochlorothiazide use

| Subgroup | Cases | Controls | Crude OR | Adjusted OR |
|----------|-------|----------|----------|-------------|
| Nonuse   | 494   | 55 666   | 1.0 (ref.) | 1.0 (ref.) |
| Cumulative duration of use | | | | |
| 0–1 year | 22    | 2365     | 1.1 (0.7–1.6) | 1.0 (0.7–1.6) |
| 1–2 years| 13    | 1091     | 1.3 (0.7–2.3) | 1.3 (0.7–2.2) |
| 2–3 years| 5     | 821      | 0.7 (0.3–1.7) | 0.7 (0.3–1.7) |
| 3–5 years| 25    | 1256     | 2.3 (1.5–3.5) | 2.3 (1.5–3.4) |
| 5+ years | 74    | 1868     | 4.7 (3.6–6.0) | 4.5 (3.5–5.9) |
| Intensity of use amongst high-users | | | | |
| 6.25 mg day⁻¹ | (n < 5) | (n < 5) | (-) | (-) |
| 12.5 mg day⁻¹ | 13    | 672      | 2.3 (1.3–4.0) | 2.3 (1.3–4.0) |
| 18.75 mg day⁻¹ | 5     | 153      | 4.0 (1.6–9.9) | 3.8 (1.5–9.5) |
| 25 mg day⁻¹ | 44    | 745      | 7.0 (5.1–9.8) | 6.7 (4.8–9.3) |
| ≥32.25 mg da⁻¹y | 20    | 448      | 5.4 (3.4–8.5) | 4.9 (3.0–7.8) |

aAdjusted for age, gender and calendar time (by risk-set matching and conditional analysis). bFully adjusted model, additionally adjusted for (i) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines and amiodarone; (ii) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs or statins; (iii) history of heavy alcohol consumption, diabetes or chronic obstructive pulmonary disease; (iv) history of nonmelanoma skin cancer; (v) Charlson Comorbidity Index score (0: low; 1–2: medium; or ≥3: high); and (vi) highest achieved education (short, medium, long or unknown). cThe duration of use assigned to each prescription was estimated assuming an intake of one tablet daily whilst not allowing stockpiling. dRestricted to those with high use of hydrochlorothiazide (≥25 000 mg). Intensity of use was estimated by dividing the total amount of drug filled with the estimated cumulative duration of use, whilst rounding to the nearest value of the categories.
antihypertensives. Theoretically, amiloride use could have contributed to the increased risk observed with overall use of HCTZ, but current evidence rather suggests that amiloride may possess antineoplastic effects [33]. Furthermore, a similar dose–response pattern for HCTZ was observed in our study when use of amiloride was excluded. To our knowledge, the association between HCTZ use and lip cancer risk has hitherto only been specifically addressed in the study by Friedman et al. [4]. However, several epidemiological studies of various photosensitizing diuretics, including HCTZ, have indicated that HCTZ use may increase skin cancer risk [6, 8, 9, 26, 27, 34], notably for SCC, but results are inconsistent [6, 9]. HCTZ use was common in a US case series of patients with a history of multiple SCCs [35], and experimental data support a carcinogenic potential of HCTZ [5–7]. The hypothesis is that HCTZ and other drugs with photosensitizing properties may influence cancer risk at sun-exposed sites and may also induce a chronic inflammatory reaction [5, 6].

We found no association between bendroflumethiazide use and lip cancer risk, even with high cumulative use. An explanation for this seemingly inconsistent risk pattern for photosensitizing drugs within the same chemical class [23] would be that the photosensitizing effect varies with the molar concentrations of the drug independently of its diuretic action. In cell and mouse models, bendroflumethiazide has similar photosensitizing properties as HCTZ at equimolar concentrations [30, 31]. However, bendroflumethiazide is a much more potent diuretic and is typically used at 10 times lower doses and has a threefold shorter half-life [36, 37], thus resulting in an overall 30-fold lower molar concentration at therapeutically equivalent doses.

Conclusion

We found a strong association between HCTZ use and SCC of the lip. The high odds ratios, evidence of specificity for HCTZ use compared to use of other
diuretics or nondiuretic antihypertensives, and the plausible biological mechanism of photosensitivity support a causal relationship between HCTZ use and risk of lip cancer. Given the considerable use of HCTZ worldwide, such numbers and attributable proportions are not negligible when drugs comparable in indications and efficacy to HCTZ are available.

Conflicts of interest statement

Anton Pottegård, Jesper Hallas and Mathias T. Sørensen have participated in research projects, unrelated to the present study, using grants provided by LEO Pharma (manufacturer of bendroflumethiazide) to the institution where the authors were employed. The remaining authors declare no conflict of interests. The work was funded by the Danish Council for Independent Research [4004-00234B]. The funding source had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; or preparation, review or approval of the manuscript.

Acknowledgements

Chris B. Jakobsen (the Danish Medicine Agency) is acknowledged for valuable help with identifying the

Table 5 Association between exposure to bendroflumethiazide or calcium-channel blockers and risk of squamous cell carcinoma of the lip, according to cumulative amount of use

| Subgroup                        | Cases   | Controls | Crude ORa | Adjusted ORb |
|---------------------------------|---------|----------|-----------|--------------|
| **Bendroflumethiazide**         |         |          |           |              |
| Nonuse                          | 449     | 45 763   | 1.0 (ref.)| 1.0 (ref.)   |
| Ever-use                        | 184     | 17 304   | 1.1 (0.9–1.3) | 1.0 (0.8–1.2) |
| Long-term use (≥2500 mg)        | 71      | 7262     | 1.0 (0.8–1.3) | 1.0 (0.8–1.3) |
| **Cumulative amount**           |         |          |           |              |
| 1–499 mg                        | 50      | 4341     | 1.2 (0.9–1.6) | 1.1 (0.8–1.5) |
| 500–999 mg                      | 27      | 2273     | 1.2 (0.8–1.8) | 1.1 (0.8–1.7) |
| 1000–2499 mg                    | 36      | 3428     | 1.1 (0.7–1.5) | 1.0 (0.7–1.4) |
| 2500–4999 mg                    | 29      | 3148     | 0.9 (0.6–1.4) | 0.9 (0.6–1.4) |
| ≥5000 mg                        | 42      | 4114     | 1.0 (0.7–1.5) | 1.1 (0.8–1.5) |
| **Group 2 calcium-channel blockers, excluding nifedipine** | | | | |
| Nonuse                          | 496     | 51 915   | 1.0 (ref.) | 1.0 (ref.)   |
| Ever-use                        | 137     | 11 152   | 1.3 (1.1–1.6) | 1.1 (0.9–1.4) |
| Long-term use (≥1000 DDD)       | 70      | 5714     | 1.3 (1.0–1.7) | 1.1 (0.8–1.5) |
| **Cumulative amount**           |         |          |           |              |
| 1–199 DDD                       | 24      | 2092     | 1.2 (0.8–1.9) | 1.0 (0.7–1.5) |
| 200–399 DDD                     | 14      | 1249     | 1.3 (0.7–2.1) | 1.0 (0.6–1.7) |
| 400–999 DDD                     | 29      | 2097     | 1.4 (1.0–2.1) | 1.2 (0.8–1.7) |
| 1000–1999 DDD                   | 19      | 1928     | 1.1 (0.7–1.7) | 0.9 (0.6–1.4) |
| ≥2000 DDD                       | 51      | 3786     | 1.5 (1.1–2.0) | 1.2 (0.9–1.6) |

DDD, defined daily doses. aAdjusted for age, gender and calendar time (by risk-set matching and conditional analysis). bFully adjusted model, additionally adjusted for (i) use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoguanolines and amiodarone; (ii) aspirin, nonaspirin nonsteroidal anti-inflammatory drugs or statins; (iii) history of heavy alcohol consumption, diabetes or chronic obstructive pulmonary disease; (iv) history of nonmelanoma skin cancer; (v) Charlson Comorbidity Index score (0: low; 1–2: medium; or ≥3: high); (vi) highest achieved education (short, medium, long or unknown); and (vii) use of hydrochlorothiazide. 2.5 mg of bendroflumethiazide is equivalent to 25 mg of hydrochlorothiazide. Use of calcium-channel blockers was estimated in DDD as an aggregate measure of exposure to different calcium-channel blockers. One DDD is equivalent to, for example, 5 mg of amlodipine, 5 mg of feledipine and 10 mg of lercanidipine (see www.whocc.no/atc_ddd_index).
hydrochlorothiazide content of combination products no longer marketed in Denmark. Drs Kaare Christensen and Maja Hellfritzsch (University of Southern Denmark) are acknowledged for valuable input on the manuscript.

References

1 Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007; 167: 141–7.
2 Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012; 126: 2105–14.
3 Friedman GD, Udaltsova N, Chan J, Quesenberry CP, Habel LA. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control 2009; 20: 1821–35.
4 Friedman GD, Asgari MM, Warton EM, Chan J, Habel LA. Antihypertensive drugs and lip cancer in non-Hispanic whites. Arch Intern Med 2012; 172: 1246–51.
5 Kunisada M, Masaki T, Ono R et al. Hydrochlorothiazide enhances UVA-induced DNA damage. Photochem Photobiol 2013; 89: 649–54.
6 International Agency for Research on Cancer. Some Drugs and Herbal Products. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 108. Lyon: International Agency for Research on Cancer, 2015.
7 O’Gorman SM, Murphy GM. Photosensitizing medications and photocarcinogenesis. Photodermatol Photoimmunol Photomed 2014; 30: 8–14.
8 Jensen AØ, Thomsen HF, Engebjer GC, Olesen AB, Sørensen HT. Use of photosensitising diuretics and risk of skin cancer: a population-based case-control study. Br J Cancer 2008; 99: 1522–8.
9 Schmidt SAJ, Schmidt M, Mehnert F, Lemeshow S, Sørensen HT. Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol 2015; 29: 1545–54.
10 Pottegård A, Friis S, Christensen RD, Habel LA, Gagne J, Hallas J. Identification of associations between prescribed medications and cancer: a nationwide screening study. EBioMedicine 2016; 7: 73–9.
11 Friis S, Kesminiene A, Eapina C, Auvinen A, Straif K, Schüz J. European code against cancer 4th edition: medical exposures, including hormone therapy, and cancer. Cancer Epidemiol 2015; 39(Suppl 1): S107–19.
12 Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39: 42–5.
13 Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol 2016; pii: dyw213. [Epub ahead of print].
14 Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish national patient registry: a review of content, data quality, and research potential. Clin Epidemiol 2015; 7: 449–90.
15 Jensen VM, Rasmussen AW. Danish Education Registers. Scand J Public Health 2011; 39: 91–4.
16 Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39: 22–5.
17 Schmidt M, Pedersen L, Sørensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol 2014; 29: 541–9.
18 Honda KS. HIV and skin cancer. Dermatol Clin 2006; 24: 521–30. vii.
19 Jensen AØ, Olesen AB, Dethlefsen C, Sørensen HT, Karagas MR. Chronic diseases requiring hospitalization and risk of non-melanoma skin cancers—a population based study from Denmark. J Invest Dermatol 2008; 128: 926–31.
20 Pedersen EG, Pottegård A, Hallas J et al. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol 2013; 20: 942–8.
21 Jiyad Z, Olsen CM, Burke MT, Isbel NM, Green AC. Azathioprine and risk of skin cancer in organ transplant recipients: systematic review and meta-analysis. Am J Transplant 2016; 16: 3490–3503.
22 Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd ed. Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins, 2008.
23 WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2015. 2014, Oslo.
24 Pottegård A, Hallas J. New use of prescription drugs prior to a cancer diagnosis. Pharmacoepidemiol Drug Saf 2016; 25: 223–227.
25 Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf 2011; 34: 821–37.
26 Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR. Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case-control study. J Invest Dermatol 2013; 133: 1950–5.
27 Kaee J, Boyd HA, Hansen AV, Wulf HC, Wohlfarth J, Melbye M. Photosensitizing medication use and risk of skin cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 2942–9.
28 Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen HT. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011; 11: 83.
29 Charlson ME, Pompei P, Alex KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–83.
30 Selvaag E, Anholt H, Moan J, Thune P. Phototoxicity to sulphonamide derived oral antidiabetics and diuretics. Comparative in vitro and in vivo investigations. vivo Athens Greece 1997; 11: 103–7.
31 Anon. Hydrochlorothiazide and bendroflumethiazide in low doses—a comparative trial. Acta Pharmacol Toxicol (Copenh) 1984; 54(Suppl 1): 47–51.
32 Schmidt M, Hallas J, Laursen M, Friis S. The Danish online drug use statistics (MEDSTAT). Int J Epidemiol 2016; 45: 1401–02g.
33 Matthews H, Ranson M, Kelso MJ. Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty? Int J Cancer 2011; 129: 2051–61.
34 de Vries E, Trakatelli M, Kalabalikis D et al. Known and potential new risk factors for skin cancer in European populations: a multicentre case-control study. Br J Dermatol 2012; 167(Suppl 2): 1–13.
35 Cognetta AB, Wolfe CM, Heinrichs E. Hydrochlorothiazide Use and Skin Cancer: a Mohs Surgeon’s Concern. Dermatol Surg 2016; 42: 1107–9.
36 Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977; 12: 297–303.
37 Borgström L, Johansson CG, Larsson H, Lenander R. Pharmacokinetics of bendroflumethiazide after low oral doses. J Pharmacokinet Biopharm 1981; 9: 431–41.

Correspondence: Anton Pottegård, Clinical Pharmacology and Pharmacy, University of Southern Denmark, JB Winsløwsvej 19, 25000 Odense C, Denmark.
(e-mail: apottegaard@health.sdu.dk)

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Effect of confounder adjustment.

Table S2. ACE inhibitors, ATII antagonists and furosemide and risk of squamous cell carcinoma.

Table S3. Effect of lag-time.

Appendix S1. Danish Nationwide Health Registries.

Appendix S2. Codes and definitions.